UBP18 Antibody

What is USP18/UBP18 and why is it important in immunological research?

USP18 (Ubiquitin-specific peptidase 18) is a deubiquitinating enzyme that functions primarily as a deISGlase, removing interferon-stimulated gene 15 (ISG15) from substrate proteins. It plays dual roles in cellular immunity through both enzymatic and non-enzymatic mechanisms. The importance of USP18 in immunological research stems from its critical functions in:

• Regulating type I interferon signaling pathways

• Modulating antiviral immune responses

• Facilitating K63-linked polyubiquitination and aggregation of MAVS (mitochondrial antiviral-signaling protein)

• Serving as a negative regulator of interferon signaling by competing with JAK for interaction with IFNAR

Understanding USP18's functions provides valuable insights into innate immunity mechanisms and potential therapeutic targets for viral infections .

What are the common alternative names and gene designations for USP18/UBP18?

When searching literature or antibody resources, researchers should be aware of the various nomenclature used for this protein:

This comprehensive understanding of nomenclature is essential for thorough literature searches and proper experimental design when working with USP18 antibodies .

What applications are USP18/UBP18 antibodies typically used for?

USP18/UBP18 antibodies are versatile tools in molecular and cellular research, with applications spanning multiple techniques:

• Western Blot (WB): For detecting USP18 protein expression levels in cell or tissue lysates

• Immunohistochemistry (IHC): For visualizing USP18 localization in tissue sections

• Immunofluorescence (IF): For examining subcellular localization, particularly mitochondrial association

• ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative measurement of USP18 levels

• Co-immunoprecipitation: For studying protein-protein interactions, such as USP18-MAVS complex formation

The choice of antibody application should be guided by experimental goals and validated reactivity information. Most commercially available USP18 antibodies demonstrate reactivity with human, mouse, and rat proteins, making them suitable for comparative studies across these species .

How does USP18 subcellular localization affect experimental design when using USP18 antibodies?

USP18's subcellular localization is dynamic and context-dependent, which significantly impacts experimental design when using antibodies:

• Mitochondrial association: USP18 enriches in mitochondrial fractions upon RNA virus infection (e.g., Sendai virus), suggesting temporal regulation of its localization. When designing immunofluorescence experiments, researchers should consider time-course analyses after viral infection to capture this dynamic process.

• Cytoplasmic vs. mitochondrial distribution: Under basal conditions, USP18 shows primarily cytoplasmic distribution, but stimuli like viral infection trigger its mitochondrial translocation. Subcellular fractionation coupled with Western blotting is recommended to accurately track this translocation.

• Co-localization studies: USP18 functions as a scaffold for other proteins like TRIM31, facilitating their relocalization to mitochondria. Dual-labeling immunofluorescence approaches with appropriate controls are essential for such studies.

Researchers should employ mitochondrial markers (e.g., TOM20) alongside USP18 antibodies to confirm mitochondrial localization. Additionally, extraction protocols should be optimized to preserve mitochondrial integrity when studying USP18's mitochondrial functions .

How can researchers distinguish between enzymatic and non-enzymatic functions of USP18 in experimental settings?

Distinguishing between USP18's enzymatic (deISGylase) and non-enzymatic (scaffold) functions requires careful experimental design:

Methodological approaches:

• Catalytic mutant studies: Utilize the USP18-C61A mutant, which lacks enzymatic activity but retains scaffold functions. Compare wild-type USP18 with C61A mutant to differentiate enzymatic from non-enzymatic effects.

• Domain-specific antibodies: Select antibodies targeting different USP18 domains to block specific functions.

• Context-dependent analysis: Analyze USP18 function in different viral infections. For example, the catalytic activity is dispensable for resistance against HSV-1 (DNA virus) but important for influenza B virus (RNA virus) responses.

• Interaction studies: Use co-immunoprecipitation with antibodies against USP18 to identify interaction partners relevant to each function (e.g., MAVS, TRIM31 for non-enzymatic functions versus ISG15-conjugated proteins for enzymatic functions).

• Complementation experiments: In USP18-deficient cells, reintroduce either wild-type or C61A mutant USP18 to determine which functions are restored.

This multifaceted approach enables researchers to delineate the distinct contributions of USP18's enzymatic and scaffolding activities in immune regulation .

What are the critical considerations when validating USP18/UBP18 antibody specificity?

Antibody validation is essential for reliable USP18 research. Critical considerations include:

Validation strategies:

• Genetic controls: Use USP18-knockout or USP18-deficient cells/tissues as negative controls to verify antibody specificity. The absence of signal in these samples confirms specificity.

• Expression systems: Test antibody recognition of recombinant USP18 protein with known concentration as positive control.

• Pre-absorption tests: Pre-incubate antibody with purified USP18 antigen before application in immunoassays to confirm that signals can be competitively blocked.

• Cross-reactivity assessment: Evaluate potential cross-reactivity with other USP family members, particularly those with high sequence homology (e.g., USP20).

• Stimulus-responsive detection: Verify that the antibody detects increased USP18 expression following type I interferon stimulation or viral infection, which induces USP18 expression.

• Multiple antibody validation: When possible, validate results using multiple antibodies targeting different epitopes of USP18.

• Application-specific validation: Remember that an antibody validated for Western blot may not perform equally well in immunohistochemistry or immunoprecipitation applications.

What are the optimal sample preparation methods for detecting USP18 in different experimental contexts?

Proper sample preparation is crucial for accurate USP18 detection. Methodological considerations vary by application:

For Western Blot analysis:

• Use RIPA buffer supplemented with protease inhibitors and deubiquitinase inhibitors (e.g., N-ethylmaleimide) to preserve USP18 and its substrates

• Include phosphatase inhibitors when studying USP18 in signaling pathways

• Sonicate samples briefly to shear DNA and reduce sample viscosity

• For mitochondrial USP18, employ mitochondrial isolation protocols before lysis

For Immunofluorescence/Immunohistochemistry:

• Fixation: 4% paraformaldehyde (10-15 minutes) preserves USP18 structure while maintaining cellular architecture

• Permeabilization: 0.1-0.2% Triton X-100 for adequate antibody access to intracellular USP18

• Antigen retrieval: For formalin-fixed tissues, citrate buffer (pH 6.0) heat-mediated retrieval improves USP18 detection

• Blocking: 5% BSA or 10% normal serum to reduce non-specific binding

For Co-immunoprecipitation:

• Use gentler lysis buffers (e.g., NP-40-based) to preserve protein-protein interactions

• Perform lysate pre-clearing with Protein A/G beads to reduce non-specific binding

• Crosslinking may be necessary to capture transient interactions of USP18 with partners like MAVS

For subcellular fractionation:

• Gentle homogenization techniques prevent mitochondrial damage when studying mitochondria-associated USP18

• Differential centrifugation steps must be carefully controlled to achieve clean fractions

• Verification of fraction purity using organelle markers (e.g., VDAC for mitochondria, GAPDH for cytosol) is essential

These optimized protocols enhance detection sensitivity and specificity when working with USP18 antibodies .

How should researchers design experiments to study USP18's role in antiviral signaling using antibodies?

Designing experiments to study USP18's role in antiviral signaling requires careful consideration of several methodological aspects:

Experimental design framework:

• Stimulus selection: Choose appropriate viral stimuli (e.g., Sendai virus for RNA sensing pathways via RIG-I, HSV-1 for DNA sensing pathways) or viral mimics (poly(I:C) for RNA sensing, poly(dA:dT) for DNA sensing).

• Time-course analysis: Monitor USP18 expression, localization, and interactions at multiple time points (typically 0, 2, 4, 8, 12, 24 hours post-stimulation) to capture the dynamic nature of antiviral responses.

• Genetic manipulation approaches:

  • Loss-of-function: siRNA knockdown, CRISPR/Cas9 knockout, or USP18-deficient cells/mice

  • Gain-of-function: Overexpression of wild-type USP18 or catalytic mutant (C61A)

  • Domain mapping: Expression of truncated USP18 constructs to identify functional domains

• Readout selection:

  • Signaling events: Monitor MAVS aggregation, TBK1/IRF3 phosphorylation

  • Transcriptional responses: Measure IFN-β, ISG mRNA levels

  • Protein ubiquitination: Analyze K63-linked ubiquitination of MAVS

  • Viral replication: Assess viral loads using plaque assays or qPCR

• Subcellular analysis: Use fractionation and immunofluorescence to track USP18 relocalization to mitochondria during infection.

• Interaction studies: Perform co-immunoprecipitation with USP18 antibodies to identify viral infection-induced interaction partners.

This systematic approach allows for comprehensive characterization of USP18's multifaceted roles in antiviral immunity .

What controls are essential when using USP18/UBP18 antibodies in immunoprecipitation studies?

Robust controls are critical for reliable immunoprecipitation (IP) experiments with USP18 antibodies:

Essential controls:

• Input control: Always analyze a small portion (5-10%) of pre-IP lysate to confirm target protein presence and establish relative enrichment after IP.

• Isotype control: Use matched isotype IgG from the same species as the USP18 antibody to identify non-specific binding.

• Genetic negative control: When available, include lysates from USP18-knockout or knockdown cells to confirm antibody specificity.

• Stimulus-dependent controls: Compare IPs from unstimulated versus stimulated conditions (e.g., before and after viral infection) to capture condition-specific interactions.

• Reciprocal IP: Confirm protein-protein interactions by performing reverse IP (e.g., IP with MAVS antibody to detect USP18).

• Competitive peptide control: Pre-incubate USP18 antibody with immunizing peptide to demonstrate binding specificity.

• Antibody-free control: Include beads-only condition to identify proteins that bind non-specifically to the matrix.

• Ubiquitination controls: When studying USP18's effect on protein ubiquitination, include deubiquitinase inhibitors in lysis buffers and consider using tandem ubiquitin binding entities (TUBEs) to enrich ubiquitinated proteins.

How should researchers interpret changes in USP18 expression patterns across different experimental conditions?

Interpreting USP18 expression changes requires consideration of multiple factors that influence its regulation:

Interpretation framework:

• Baseline vs. induced expression:

  • USP18 is typically expressed at low levels in resting cells

  • Expression is strongly induced by type I interferons and viral infection

  • Baseline changes may indicate altered immune homeostasis

• Temporal dynamics:

  • Early expression changes (2-6 hours): Usually reflect direct transcriptional activation

  • Later changes (12-24 hours): May indicate secondary effects or feedback regulation

  • Sustained expression: Consider potential pathological conditions

• Cell-type specific patterns:

  • Immune cells typically show stronger USP18 induction than non-immune cells

  • Hepatocytes exhibit particularly high USP18 expression after IFN stimulation

  • Interpret results within the appropriate cellular context

• Protein vs. mRNA correlation:

  • Discrepancies between mRNA and protein levels may indicate post-transcriptional regulation

  • Half-life considerations: USP18 protein turnover is regulated by the ubiquitin-proteasome system

  • Western blot quantification should be normalized to housekeeping proteins

• Subcellular localization changes:

  • Mitochondrial enrichment during viral infection suggests activation of antiviral functions

  • Nuclear localization may indicate non-canonical functions

  • Always correlate localization with functional readouts

• Isoform-specific expression:

  • Multiple USP18 splice variants exist with potentially different functions

  • Antibody epitope location may affect detection of specific isoforms

  • Consider using isoform-specific PCR primers alongside antibody detection

This comprehensive interpretation approach helps researchers distinguish physiologically relevant USP18 changes from experimental artifacts .

What are the key considerations when analyzing USP18's role in K63-linked ubiquitination using antibody-based methods?

Analyzing USP18's role in K63-linked ubiquitination presents specific technical challenges that require careful experimental design:

Methodological considerations:

• Specific ubiquitin chain detection:

  • Use K63-linkage specific antibodies that recognize only K63-linked polyubiquitin chains

  • Confirm specificity using recombinant ubiquitin chain standards of different linkage types

  • Consider mass spectrometry approaches for unambiguous linkage identification

• Preserving ubiquitination status:

  • Include deubiquitinase inhibitors (N-ethylmaleimide, PR-619) in lysis buffers

  • Use fresh samples, as freeze-thaw cycles can affect ubiquitin chain integrity

  • Process samples rapidly at 4°C to minimize post-lysis deubiquitination

• Controls for ubiquitination studies:

  • Positive control: Cells treated with proteasome inhibitors (for K48-linked chains) or TNFα (for K63-linked chains)

  • Negative control: Expression of linkage-specific deubiquitinases

  • Ubiquitin mutants: K63R ubiquitin mutant expression to confirm linkage specificity

• Sequential immunoprecipitation approach:

  • First IP: Target protein of interest (e.g., MAVS)

  • Second IP: K63-linked ubiquitin chains

  • This two-step process increases specificity and reduces background

• Ubiquitination site mapping:

  • Mutagenesis of predicted ubiquitination sites (lysine to arginine)

  • Use of truncation mutants to identify domains subject to ubiquitination

  • Correlation with in silico prediction tools for ubiquitination sites

• Enzymatic vs. scaffold function discrimination:

  • Compare wild-type USP18 with catalytic mutant (C61A)

  • Determine if USP18 directly deubiquitinates the target or facilitates ubiquitination by recruiting E3 ligases (e.g., TRIM31)

These approaches enable accurate assessment of USP18's complex roles in modulating K63-linked ubiquitination of target proteins like MAVS in antiviral signaling .

How can contradictory results with USP18/UBP18 antibodies be reconciled in research literature?

Contradictory results with USP18 antibodies in the literature are not uncommon and may arise from several factors:

Reconciliation strategies:

• Antibody variation:

  • Different epitope recognition: Antibodies targeting different regions of USP18 may yield varying results, especially if conformational changes occur

  • Clone-specific differences: Monoclonal vs. polyclonal antibodies offer different advantages and limitations

  • Solution: Compare antibody data sheets for epitope information and validation methods

• Context-dependent functions:

  • Cell type specificity: USP18 functions differently across cell types (immune vs. non-immune cells)

  • Stimulus-dependent effects: USP18 exhibits different roles depending on the viral stimulus (RNA vs. DNA viruses)

  • Solution: Directly compare experimental systems and stimulation conditions

• Dual mechanisms of action:

  • Enzymatic role (ISG15 deconjugation) vs. non-enzymatic role (scaffolding)

  • IFNAR inhibition vs. direct antiviral signaling effects

  • Solution: Use USP18-C61A mutant to distinguish catalytic from non-catalytic functions

• Technical variations:

  • Sample preparation differences: Lysis conditions affect protein interactions and epitope accessibility

  • Detection methods: Chemiluminescence vs. fluorescence-based detection offers different sensitivities

  • Solution: Standardize protocols and use multiple detection methods

• Genetic background effects:

  • Mouse strain differences: Various genetic backgrounds may influence USP18 function

  • Compensatory mechanisms in knockout models: Chronic vs. acute loss of USP18

  • Solution: Use multiple genetic models and acute depletion systems

• Publication bias considerations:

  • Negative results often go unpublished, skewing the literature

  • Solution: Contact authors directly regarding unpublished observations and protocol details

This systematic approach to reconciling contradictory results promotes a more nuanced understanding of USP18 biology and improves experimental reproducibility .